Biogen (BIIB) tops Q2 expectations, raises profit guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Biogen (BIIB) PT Raised to $292 at RBC Capital
August 2, 2024 6:24 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $292.00 (from $282.00) while maintaining a Outperform rating.
The analyst comments "BIIB's 2Q was better than today's stock action might suggest; while the beat was in partially driven by a few... More
Biogen (BIIB) Tops Q2 EPS by 127c; profit guidance raised
August 1, 2024 6:59 AM EDTBiogen (NASDAQ: BIIB) reported Q2 EPS of $5.28, $1.27 better than the analyst estimate of $4.01. Revenue for the quarter came in at $2.47 billion versus the consensus estimate of $2.39 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.75-$16.25, versus the consensus of $15.58.... More
Biogen lifts profit forecast, signals progress in turnaround effort
August 1, 2024 6:50 AM EDTBy Manas Mishra and Mariam Sunny
(Reuters) -Biogen lifted its full-year profit forecast on Thursday due to cost cuts and better-than-expected sales of its various treatments, even as the U.S. adoption of its Alzheimer's drug remains slow.
CEO Christopher Viehbacher, who is spearheading a turnaround at Biogen since taking over the top job in 2022, said the company was now positioned for growth after a series of cost-cutting efforts, multiple acquisitions and a... More
Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients
July 30, 2024 5:00 PM EDTEisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (A) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, USA, and virtually. Dual-acting lecanemab is the only early AD treatment widely available to support neuronal function by clearing the highly toxic... More
